October 5, 2017
FDA issues Safety Alert for intraocular TMV injections
Editor's Note
The Food & Drug Administration (FDA) on October 3 issued a Safety Alert saying the agency had received an adverse event report on a patient who was diagnosed with bilateral hemorrhagic occlusive retinal vasculitis after being administered injections of a compounded triamcinolone, moxifloxacin, vancomycin (TMV) formulation in each eye at the end of cataract surgery procedures that were done 2 weeks apart.
The TMV formulation was compounded by Imprimis Pharmaceuticals (Ledgewood, New Jersey).
Free Daily News
- Study: Education, exercise improve knee OA with or without prior surgery
- Study: Early surgery outperforms endoscopy for long-term pancreatitis
- Study: Blood thinner, NSAID combination raises bleeding risk
- Hospital financial report predicts stability, high cybersecurity costs for 2025
- IV fluid shortage drives innovation in hospital hydration practices
- FDA Class 1 recalls target anesthesia workstations, ambulatory infusion pumps, ventilators
- Five leadership lessons from an ASC CEO
- CMS final rule for CY 2025: Key updates impacting Medicare payments, quality programs
- GAO urges HHS to strengthen cybersecurity oversight
- Study: GLP-1s reduce TKA complications for non-diabetic patients with obesity
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement